Abstract

The present invention provides a method of treating cancer by providing to a subject in need thereof an immunogenic composition comprising a nucleic acid construct encoding a polypeptide comprising CTL epitopes PSMA288-297 and PRAME425-433, or a cross-reactive analogue. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.


Claims
Download PDF
Document Preview
Document History
  • Publication: Mar 18, 2014
  • Application: Jul 8, 2011
    US US 201113179042 A
  • Priority: Jul 8, 2011
    US US 201113179042 A
  • Priority: Jun 16, 2006
    US US 45461606 A
  • Priority: Jun 17, 2005
    US US 69157905 P

Download Citation


Sign in to the Lens

Feedback